Monoclonal B-cell lymphocytosis: Update on diagnosis, clinical outcome, and counseling

Sameer A Parikh, Neil Elliot Kay, Tait D. Shanafelt

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Monoclonal B-cell lymphocytosis (MBL) is a clonal B-cell disorder characterized by less than 5 × 109/L B lymphocytes in the peripheral blood, with a characteristic immuno-phenotype and no lymphadenopathy or organomegaly. The vast majority of MBL cases express the immuno phenotype of chronic lymphocytic leukemia (CLL; CLL-like MBL), although non-CLL MBL also exists. CLL-like MBL, which is the focus of this review, is divided into low-count MBL (median B-cell count: 0.001 × 109/L, typically identified in population-based screening studies using highly sensitive flow cytometry assays) and high-count MBL (clinical MBL, median B-cell count: 2.9 × 109/L, typically identified during the workup of low-level lymphocytosis). Low-count MBL has an exceedingly small risk of progression to CLL, and these patients do not require any specific follow-up. In contrast, patients with high-count MBL have a 1% to 2% per year risk of progression to CLL requiring therapy, as well as a higher risk of infectious complications and secondary malignancies. Although the overall survival of high-count MBL patients collectively is similar to the age- and sex-matched general population, 5-year survival for CD38+ high-count MBL is approximately 10% to 20% lower than the general population. This review summarizes key concepts in the classification, diagnosis, and biology of CLL-like MBL and addresses several important issues in clinical management.

Original languageEnglish (US)
Pages (from-to)720-729
Number of pages10
JournalClinical Advances in Hematology and Oncology
Volume11
Issue number11
StatePublished - 2013

Fingerprint

Lymphocytosis
Counseling
B-Lymphocytes
Cell Count
Population
Phenotype
Survival

Keywords

  • Chronic lymphocytic leukemia
  • Classifcation
  • Clinical management
  • Diagnosis
  • Monoclonal B-cell lymphocytosis

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Medicine(all)

Cite this

Monoclonal B-cell lymphocytosis : Update on diagnosis, clinical outcome, and counseling. / Parikh, Sameer A; Kay, Neil Elliot; Shanafelt, Tait D.

In: Clinical Advances in Hematology and Oncology, Vol. 11, No. 11, 2013, p. 720-729.

Research output: Contribution to journalArticle

@article{ed62d58d5c38463a930620d2d5a3c0e1,
title = "Monoclonal B-cell lymphocytosis: Update on diagnosis, clinical outcome, and counseling",
abstract = "Monoclonal B-cell lymphocytosis (MBL) is a clonal B-cell disorder characterized by less than 5 × 109/L B lymphocytes in the peripheral blood, with a characteristic immuno-phenotype and no lymphadenopathy or organomegaly. The vast majority of MBL cases express the immuno phenotype of chronic lymphocytic leukemia (CLL; CLL-like MBL), although non-CLL MBL also exists. CLL-like MBL, which is the focus of this review, is divided into low-count MBL (median B-cell count: 0.001 × 109/L, typically identified in population-based screening studies using highly sensitive flow cytometry assays) and high-count MBL (clinical MBL, median B-cell count: 2.9 × 109/L, typically identified during the workup of low-level lymphocytosis). Low-count MBL has an exceedingly small risk of progression to CLL, and these patients do not require any specific follow-up. In contrast, patients with high-count MBL have a 1{\%} to 2{\%} per year risk of progression to CLL requiring therapy, as well as a higher risk of infectious complications and secondary malignancies. Although the overall survival of high-count MBL patients collectively is similar to the age- and sex-matched general population, 5-year survival for CD38+ high-count MBL is approximately 10{\%} to 20{\%} lower than the general population. This review summarizes key concepts in the classification, diagnosis, and biology of CLL-like MBL and addresses several important issues in clinical management.",
keywords = "Chronic lymphocytic leukemia, Classifcation, Clinical management, Diagnosis, Monoclonal B-cell lymphocytosis",
author = "Parikh, {Sameer A} and Kay, {Neil Elliot} and Shanafelt, {Tait D.}",
year = "2013",
language = "English (US)",
volume = "11",
pages = "720--729",
journal = "Clinical Advances in Hematology and Oncology",
issn = "1543-0790",
publisher = "Millennium Medical Publishing, Inc.",
number = "11",

}

TY - JOUR

T1 - Monoclonal B-cell lymphocytosis

T2 - Update on diagnosis, clinical outcome, and counseling

AU - Parikh, Sameer A

AU - Kay, Neil Elliot

AU - Shanafelt, Tait D.

PY - 2013

Y1 - 2013

N2 - Monoclonal B-cell lymphocytosis (MBL) is a clonal B-cell disorder characterized by less than 5 × 109/L B lymphocytes in the peripheral blood, with a characteristic immuno-phenotype and no lymphadenopathy or organomegaly. The vast majority of MBL cases express the immuno phenotype of chronic lymphocytic leukemia (CLL; CLL-like MBL), although non-CLL MBL also exists. CLL-like MBL, which is the focus of this review, is divided into low-count MBL (median B-cell count: 0.001 × 109/L, typically identified in population-based screening studies using highly sensitive flow cytometry assays) and high-count MBL (clinical MBL, median B-cell count: 2.9 × 109/L, typically identified during the workup of low-level lymphocytosis). Low-count MBL has an exceedingly small risk of progression to CLL, and these patients do not require any specific follow-up. In contrast, patients with high-count MBL have a 1% to 2% per year risk of progression to CLL requiring therapy, as well as a higher risk of infectious complications and secondary malignancies. Although the overall survival of high-count MBL patients collectively is similar to the age- and sex-matched general population, 5-year survival for CD38+ high-count MBL is approximately 10% to 20% lower than the general population. This review summarizes key concepts in the classification, diagnosis, and biology of CLL-like MBL and addresses several important issues in clinical management.

AB - Monoclonal B-cell lymphocytosis (MBL) is a clonal B-cell disorder characterized by less than 5 × 109/L B lymphocytes in the peripheral blood, with a characteristic immuno-phenotype and no lymphadenopathy or organomegaly. The vast majority of MBL cases express the immuno phenotype of chronic lymphocytic leukemia (CLL; CLL-like MBL), although non-CLL MBL also exists. CLL-like MBL, which is the focus of this review, is divided into low-count MBL (median B-cell count: 0.001 × 109/L, typically identified in population-based screening studies using highly sensitive flow cytometry assays) and high-count MBL (clinical MBL, median B-cell count: 2.9 × 109/L, typically identified during the workup of low-level lymphocytosis). Low-count MBL has an exceedingly small risk of progression to CLL, and these patients do not require any specific follow-up. In contrast, patients with high-count MBL have a 1% to 2% per year risk of progression to CLL requiring therapy, as well as a higher risk of infectious complications and secondary malignancies. Although the overall survival of high-count MBL patients collectively is similar to the age- and sex-matched general population, 5-year survival for CD38+ high-count MBL is approximately 10% to 20% lower than the general population. This review summarizes key concepts in the classification, diagnosis, and biology of CLL-like MBL and addresses several important issues in clinical management.

KW - Chronic lymphocytic leukemia

KW - Classifcation

KW - Clinical management

KW - Diagnosis

KW - Monoclonal B-cell lymphocytosis

UR - http://www.scopus.com/inward/record.url?scp=84889608334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889608334&partnerID=8YFLogxK

M3 - Article

C2 - 24896545

AN - SCOPUS:84889608334

VL - 11

SP - 720

EP - 729

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

SN - 1543-0790

IS - 11

ER -